INOMAX® Important Safety Information
INOMAX is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
Please see Full Prescribing Information.
These complimentary resources are available to you as part of our commitment to supporting you and your NICU team.
Select the resources you’d like to receive, then complete your request at the bottom of the list.
Monograph from the National Association of Neonatal Nurses (NANN) offers updated information about the role of inhaled nitric oxide (iNO) in the treatment of term and near-term neonates with hypoxic respiratory failure (HRF).
Presented at the 2013 Annual Educational Conference of the National Association of Neonatal Nurses (NANN), this monograph features a case study that examines the outcomes of treatment with inhaled nitric oxide of a near-term neonate with HRF associated with pulmonary hypertension.
A complete list of ventilators, anesthesia systems, and other respiratory care devices that are compatible with INOMAX drug delivery systems.